异甘草酸镁治疗自身免疫样药物性肝损伤的效果和安全性

杜晓菲; 陈杰; 黄春洋; 张小丹; 刘丹; 边新渠; 韩莹; 刘燕敏; 单晶

doi:10.3969/j.issn.1001-5256.2020.06.028

异甘草酸镁治疗自身免疫样药物性肝损伤的效果和安全性

DOI: 10.3969/j.issn.1001-5256.2020.06.028

首都医科大学佑安医院肝病免疫科

基金项目:

佑安肝病艾滋病基金资助课题(京佑基金〔2017〕第27号)；北京市属医院科研培育计划项目(PX2017010)；丰台区卫生系统科研项目(2017-62)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1148
- HTML全文浏览量: 121
- PDF下载量: 197
- 被引次数: 0
出版历程
- 出版日期: 2020-06-20

Clinical effect and safety of magnesium isoglycyrrhizinate in treatment of autoimmune-like drug-induced liver injury

Research funding:

摘要

摘要:
目的探索异甘草酸镁治疗自身免疫样药物性肝损伤的临床疗效和安全性。方法选取首都医科大学附属北京佑安医院2016年7月-2019年1月住院的自身免疫样药物性肝损伤患者53例为观察组,另选不伴有自身免疫现象的药物性肝损伤患者50例为对照组。所有患者给予异甘草酸镁200 mg/d,治疗4周。观察治疗前后患者肝功能情况,观察治疗前后观察组患者的免疫学指标,记录两组患者的不良反应。治疗结束后每月随访肝功能,随访时间6个月。正态分布计量资料组间比较采用t检验,非正态分布的计量资料采用Mann-Whitney U检验,计数资料组间比较采用χ2检验或Fisher精确概率检验。结果观察组治疗后与治疗前比较,ALT[35. 4（29. 2～42. 0） U/L vs 289. 0（226. 6～460. 3） U/L,Z=-8. 661,P<0. 001]、AST[46. 3（15. 6～183. 5） U/L vs306. 3（32. 2～589. 8） U/L,Z=-5. 271,P <0. 001]、GGT[77. 0（53. 2～183. 2） U/L vs 12...
- 化学性与药物性肝损伤 /
- 自身免疫疾病 /
- 治疗学 /
- 异甘草酸镁
Abstract:
Objective To investigate the clinical effect and safety of magnesium isoglycyrrhizinate in the treatment of autoimmune-like drug-induced liver injury. Methods A total of 53 patients with autoimmune-like drug-induced liver injury who were hospitalized in Beijing YouAn Hospital,Capital Medical University,from July 2016 to January 2019 was enrolled as observation group,and 50 patients with drug-induced liver injury who had no autoimmune symptoms were enrolled as control group. All patients were given magnesium isoglycyrrhizinate( 200 mg/d) for 4 weeks. Liver function and immunological indices were observed before and after treatment,and adverse reactions were recorded for all patients. Liver function was followed up every month for 6 months after treatment. The t-test was used for comparison of normally distributed continuous data between groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups.Results After treatment,the observation group had significant reductions in alanine aminotransferase( ALT) [35. 4( 29. 2-42. 0) U/L vs 289. 0( 226. 6-460. 3) U/L,Z =-8.661,P<0. 001],aspartate aminotransferase( AST) [46. 3( 15.6-183.5) U/L vs 306. 3( 32. 2-589. 8) U/L,Z =-5. 271,P < 0. 001],gamma-glutamyl transpeptidase( GGT) [77. 0( 53. 2-183. 2) U/L vs 129. 0( 77. 8-232. 5) U/L,Z =-3. 437,P =0. 001],alkaline phosphatase( ALP) [83. 1( 64. 9-83. 1) U/L vs 119. 4( 104. 9-146. 9) U/L,Z =-3. 485,P < 0. 001],and total bilirubin( TBil)( 27. 5 ±10. 3 μmol/L vs 59. 7 ±18.6 μmol/L,t =6. 673,P <0. 001),and the control group also had significant reductions in ALT[33. 1( 14. 9-106. 4) U/L vs 300. 6( 206. 8-679. 5) U/L,Z =-8. 232,P < 0. 001],AST [44. 1( 20. 8-151. 6) U/L vs 321. 7( 36. 2-553. 2) U/L,Z =-3. 549,P < 0. 001],GGT [82. 7( 50. 6-168. 5) U/L vs 133. 5( 72. 2-254. 2) U/L,Z =-2. 364,P = 0. 018],ALP [87. 6( 74. 3-139. 4) U/L vs 128. 0( 106. 3-201. 4) U/L,Z =-4. 303,P < 0. 001],and TBil( 23. 8 ± 10. 9 μmol/L vs 58. 3 ±19. 8 μmol/L,t =-8. 450,P < 0. 001); however,there were no significant differences between the two groups after treatment( P >0. 05). For the observation group,the level of Ig G decreased from 15. 8 ± 3. 2 g/L before treatment to 14. 2 ± 2. 0 g/L after treatment,and among the 22 patients with elevated Ig G( > 16 g/L) before treatment,18( 81. 8%) had an Ig G level back to normal. Among the 36 patients with positive anti-nuclear antibody,19( 52. 7%) achieved negative conversion. No serious adverse reaction was observed in the two groups. In terms of the patients who underwent liver biopsy,the observation group had a significantly higher proportion of patients with neutrophil and/or eosinophil infiltration than the control group [53. 1%( 17/32) vs 17. 5%( 3/17),χ2= 5. 785,P = 0. 016]. Conclusion Magnesium glycyrrhizinate is safe and effective in the treatment of autoimmune-like drug-induced liver injury and can thus be selected as an alternative treatment method in clinical practice.
- chemical and drug induced liver injury /
- autoimmune diseases /
- therapeutics /
- magnesium isoglycyrrhizinate

HTML全文

参考文献(18)

[1] The Study of Drug Induced Liver Disease of Chinese Medical Association. Diagnosis and treatment guideline on drug-induced liver injury[J]. J Clin Hepatol. 2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南[J]．临床肝胆病杂志，2015,31(11):1752-1769.

[2] REN MX,CHEN J,HUANG CY,etal. The clinical and pathological characteristics of drug-induced fiver injury accompanied by autoimmune phenomena[J]. J China-Japan Friendship Hosp,2018,32(5):279-282.(in Chinese)任美欣，陈杰，黄春洋，等．伴自身免疫现象的药物性肝损伤的临床和病理特点[J]．中日友好医院学报，2018,32(5):279-282.

[3] DANAN G,BENIEHOU C. Causality assessment of adverse reactions to Dmgs-A novel method based on the conclusions of international consensus meetings:Application to drug-induced liver injuries[J]. J Clin Epidemiol,1993,46(11):1323-1330.

[4] ZHOU XL,LIANG QS,SUN Y,et al. Research progress of autoimmune drug-induced liver injury[J]. Chin Hepatol,2017,22(5):460-463.(in Chinese)周晓丽，梁庆升，孙颖，等．自身免疫样药物性肝损伤研究进展[J]．肝脏，2017,22(5):460-463.

[5] HUANG CY,LIU YM,HUANG YL,et al. Drug-induced liver injury accompanied by autoimmune phenomena:An analysis of clinical cha racteristics[J]. J Clin Hepatol,2015,31(8):1303-1306.(in Chinese)黄春洋，刘燕敏，黄云丽，等．药物性肝损伤患者伴自身免疫现象的临床特点分析[J]．临床肝胆病杂志，2015,31(8):1303-1306.

[6] ALVAREZ F,BERG PA,BIANCHI FB,et al. International autoimmune hepatitis group report:Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol,1999,31(5):929-938.

[7] LIU YP,WANG R,LIANG SR,et al. Comparative analysis of clinical data between drug-induced autoimmune hepatitis and primary autoimmune hepatitis[J]. Shandong Med J,2019,59(21):54-57.(in Chinese)刘钰佩，王瑞，梁树人，等．药物诱导自身免疫性肝炎与原发自身免疫性肝炎患者临床资料对比分析[J]．山东医药，2019,59(21):54-57.

[8] CHEN J,LIANG S,FAN ZP,et al. The clinical characteristics of patients with chronic drug induced cholesteric liver disease[J]. Chin J Diffic Compl Cas,2017,16(4):400-402,406.(in Chinese)陈杰，梁珊，范作鹏，等．慢性药物性胆汁淤积性肝病34例临床特点分析[J]．疑难病杂志，2017,16(4):400-402,406.

[9] YU YC,MAO YM,CHEN CW,et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int,2017,11(3):221-241.

[10] CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al. ACG clinical guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966.

[11] MAO YM,ZENG MD,CHEN Y,et al. Magnesium isoglycyrrhizinate in the treatment of chronic lver diseases:A randomized,double-blind,multi-doses,active drug controlled,muitlcenter study[J]. Chin J Hepatol,2009,17(11):847-851.(in Chinese)茅益民，曾民德，陈勇，等．异甘草酸镁治疗ALT升高的慢性肝病的多中心、随机、双盲、多剂量、阳性药物平行对照研究[J]．中华肝脏病杂志，2009,17(11):847-851.

[12] WANG Y,WANG Z,GAO M,et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury:A phase II trial[J]. Liver Int,2019,39(11):2102-2111.

[13] ZOU X,WANG Y,PENG C,et al. Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatininduced model of liver injury[J]. Int J Mol Med,2018,42(4):2020-2030.

[14] YANG Q,WANG J,LIU R,et al. Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(-)CD69(+)subset proliferation[J]. Drug Des Devel Ther,2016,10:443-453.

[15] YASUI S,FUJIWARA K,TAWADA A,et al. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis[J]. Dig Dis Sci,2011,56(12):3638-3647.

[16] European Association for the Study of the Liver. EASL clinical practice guidelines:Autoimmune hepatitis[J]. J Hepatol,2015,63(4):971-1004.

[17] ZHOU TH,XIE Q. Research progress of chronic drug-induced liver injury[J]. Chin Hepatol,2018,23(9):825-827.(in Chinese)周天慧，谢青．慢性药物性肝损伤研究进展[J]．肝脏，2018,23(9):825-827.

[18] YU YC,FAN Y,CHEN CW. Diagnosis and treatment of druginduced liver injury[J]. J Clin Hepatol,2018,34(6):1160-1165.(in Chinese)于乐成，范晔，陈成伟．药物性肝损伤的诊断和治疗[J]．临床肝胆病杂志，2018,34(6):1160-1165.

施引文献

资源附件(0)

访问统计